Search results
Results from the WOW.Com Content Network
gamma. -Hydroxybutyric acid. gamma-Hydroxybutyric acid (GHB) (or γ-hydroxybutyric acid), also known as 4-hydroxybutanoic acid is a naturally occurring neurotransmitter and a depressant drug. It is a precursor to GABA, glutamate, and glycine in certain brain areas. It acts on the GHB receptor and is a weak agonist at the GABA B receptor.
Proteinuria is the presence of excess proteins in the urine. In healthy persons, urine contains very little protein, less than 150 mg/day; an excess is suggestive of illness. Excess protein in the urine often causes the urine to become foamy (although this symptom may also be caused by other conditions).
[2] [25] These changes in cholesterol levels were +1.2 mg/dL at 10 mg, +2.3 mg/dL at 20 mg, +3.1 mg/dL at 40 mg, and +6.0 mg/dL at 80 mg relative to –3.7 mg/dL for placebo. [2] [25] Although the increases in cholesterol levels with approved doses of suvorexant (10–20 mg) are small, they could be important over a long duration of treatment.
Phenylephrine is a selective α 1 -adrenergic receptor agonist with minimal to no β-adrenergic receptor agonist activity or induction of norepinephrine release. [5][8][15] It causes constriction of both arteries and veins. [12] Phenylephrine was patented in 1933 [16] and came into medical use in 1938. [17]
In general, serum or plasma valproic acid concentrations are in a range of 20–100 mg/L during controlled therapy, but may reach 150–1500 mg/L following acute poisoning. Monitoring of the serum level is often accomplished using commercial immunoassay techniques, although some laboratories employ gas or liquid chromatography. [ 65 ]
Blood-sugar levels naturally fluctuate throughout the day, the body normally maintaining levels between 70 and 110 mg/dL (3.9–6.1 mmol/L). [3] [2] Although 70 mg/dL (3.9 mmol/L) is the lower limit of normal glucose, symptoms of hypoglycemia usually do not occur until blood sugar has fallen to 55 mg/dL (3.0 mmol/L) or lower.
[29] [30] It is also available over-the-counter in the form of 12.5 and 25 mg oral tablets for use as a bronchodilator and as a 0.5% concentration nasal spray for use as a decongestant. [30] The drug is additionally available in combination with guaifenesin in the form of oral tablets and liquids. [30]
Primary outcome measures examined include a hemoglobin response measured by levels higher than 10 g/dL and 2 g/dL higher than the baseline hemoglobin. Responses were studied for a period of 12 weeks and for a dose of 150 mg in the morning and evening. The study began in April 2016 and is estimated to conclude in September 2017.